How blood clotting works
Haemostasis (clot formation) involves two converging pathways:
- Primary haemostasis:Platelet aggregation at the injury site, forming a platelet plug. TXA2 (thromboxane A2, from platelet arachidonic acid metabolism) is the primary amplifying signal for platelet aggregation.
- Secondary haemostasis (coagulation cascade):A series of enzyme activations (factors II, V, VII, IX, X — most requiring vitamin K for synthesis) culminates in thrombin converting fibrinogen to fibrin, stabilising the platelet plug.
Spirulina’s effects on platelets
The primary mechanism:
- GLA (gamma-linolenic acid) in spirulina is metabolised to DGLA, which is converted by COX-1 to PGE1 (prostaglandin E1). PGE1 is a vasodilator and potent inhibitor of platelet aggregation.
- DGLA also competes with arachidonic acid for COX enzymes — reducing TXA2 production (the proaggregatory prostaglandin). Less TXA2 means less platelet aggregation per activation stimulus.
This is the same mechanism by which evening primrose oil (high-GLA source) has mild antiplatelet effects. At spirulina’s GLA dose (100–130 mg/10g), the effect is modest — not clinically significant in healthy individuals, but potentially additive with antiplatelet drugs.
Vitamin K1 and warfarin
Warfarin works by inhibiting vitamin K-dependent clotting factor synthesis (factors II, VII, IX, X). The therapeutic INR (typically 2–3 for most indications) is maintained by balancing warfarin dose against dietary vitamin K intake.
Spirulina contains approximately 25–40 µg vitamin K1 per 10 g. This is:
- Less than broccoli (~110 µg/100g), spinach (~500 µg/100g), or kale (~700 µg/100g) — the main dietary vitamin K sources that affect INR
- Sufficient to shift INR if spirulina intake is inconsistent — adding or stopping 5–10 g/day spirulina represents a meaningful vitamin K change for someone on warfarin
The management principle for warfarin + spirulina is consistency — not avoidance. Consistent daily spirulina intake at a fixed dose allows INR to stabilise at the new vitamin K level. Stopping and starting spirulina is the problem; consistent use can be accommodated by warfarin dose adjustment.
Antiplatelet drug interactions
- Aspirin (antiplatelet dose 75–100 mg/day):Aspirin irreversibly acetylates COX-1 in platelets, blocking TXA2. Spirulina’s PGE1-mediated antiplatelet effect is additive. Unlikely to cause clinically significant bleeding at standard spirulina doses, but those on aspirin should be aware.
- Clopidogrel (Plavix):A P2Y12 receptor blocker — different mechanism from spirulina’s GLA pathway. Additive antiplatelet effect possible. Inform the prescribing cardiologist before starting spirulina if on dual antiplatelet therapy.
- Rivaroxaban, apixaban (direct oral anticoagulants — DOACs):These are not vitamin K-dependent — spirulina’s vitamin K1 does not interact with DOACs through the coagulation factor pathway. The antiplatelet GLA effect is still present but less concerning than with warfarin.
Pre-surgery considerations
Before elective surgery, surgeons typically request cessation of any supplements with antiplatelet potential. Spirulina’s mild antiplatelet effect via GLA is unlikely to significantly increase surgical bleeding, but the standard recommendation is:
- Stop spirulina 1–2 weeks before elective surgery as a precaution
- Inform the surgical team about spirulina use during pre-operative assessment
- For emergency surgery, the effect is too mild to require specific reversal
Who has elevated bleeding concern
- Patients on warfarin — maintain consistent daily dose, inform anticoagulation clinic, and check INR at 2–3 weeks after starting
- Patients on dual antiplatelet therapy (aspirin + clopidogrel) — inform cardiologist
- Haemophilia and von Willebrand disease — platelet function changes are relevant; haematologist guidance required
- Anyone with unexplained bruising or bleeding history — investigate before adding any supplement with antiplatelet potential
Who doesn’t need concern
- Healthy individuals with no anticoagulant or antiplatelet medication — spirulina’s antiplatelet effect is mild and consistent with many common foods
- Patients on DOACs (apixaban, rivaroxaban, dabigatran) — vitamin K1 content doesn’t affect these drugs. The antiplatelet effect is still present but unlikely clinically significant
- Patients on statins — no relevant interaction with spirulina’s clotting effects
GLA and cardiovascular protection
The same PGE1-mediated antiplatelet effect that raises cautions in anticoagulated patients is a cardiovascular-protective mechanism in healthy individuals. Elevated TXA2 activity (from excess arachidonic acid in Western diets) increases thrombotic risk. GLA’s TXA2 reduction and PGE1 promotion represents a gentler, dietary-level cardiovascular protection mechanism.